Polypodium leucotomos Extract use to prevent and reduce the risk of infectious diseases in high performance athletes

Figures & data

Table 1 Prevalence of infectious processes in the control group and study group (Polypodium leucotomos Extract-treated)

Infectious processes: control group	Infectious processes: study group
Nonbacterial pharyngoamygdalitis (n = 10)	Nonbacterial pharyngoamygdalitis (n = 2)
Bacterial pharyngoamygdalitis (n = 2)	Bacterial pharyngoamygdalitis (n = 1)
Rhinopharyngitis (n = 4)	Conjunctivitis (n = 2)
Viral otitis (n = 3)	Acute gastroenteritis (n = 1)
Bacterial otitis of the lower tract (n = 3)	Dental abscess (n = 1)
Respiratory tract infection (n = 5)
Influenza syndrome (n = 1)
Total: 28 cases	Total: 7 cases

Figure 1 Percentage of athletes who presented pathologies in the control group and the study group (Polypodium leucotomos Extract-treated).

Figure 2 Number of athletes with conditions of viral/bacterial pharyngoamygdalitis in the control group and study group (Polypodium leucotomos Extract-treated).

Figure 3 Number of athletes with relapses in the control group and study group (Polypodium leucotomos Extract-treated).